Paper Details

  1. Home
  2. Paper Details

Prevention of poststroke depression with milnacipran in patients with acute ischemic stroke: a double-blind randomized placebo-controlled trial.

Author: ChouShih-Yong, HungTai-Hsin, SuJian-An, TsaiChing-Shu, TsangHin-Yeung, WuChen-Long

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.

Overview

Milnacipran is a safe and effective medication for preventing poststroke depression (PSD) in patients who have suffered a stroke. In a double-blind, randomized, placebo-controlled trial involving 92 patients, milnacipran significantly reduced the incidence of depression, with only 2.22% of patients in the milnacipran group developing PSD compared to 15.22% in the placebo group.
Paper Details　
Original Abstract of the Article :
Poststroke depression (PSD) is one of the most frequent neuropsychiatric consequences of stroke. It has been shown to be associated with both impaired recovery and increased mortality. The purpose of this study is to investigate the prophylactic effect of milnacipran in PSD. Ninety-two patients were...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/YIC.0b013e32834a5c64

データ提供：米国国立医学図書館（NLM）

Milnacipran: A Potential Shield Against Poststroke Depression

This research explores the potential of milnacipran, an antidepressant medication, in preventing poststroke depression (PSD), a common and debilitating consequence of stroke. The authors conducted a double-blind, randomized, placebo-controlled trial involving 92 patients who had experienced an acute ischemic stroke. The study followed these patients for 12 months, assessing the incidence of PSD in both the milnacipran and placebo groups. The findings revealed a significantly lower incidence of depression in the milnacipran group, suggesting that this medication may effectively prevent PSD.

Milnacipran: A Beacon of Hope for Stroke Recovery

The study provides compelling evidence for the potential of milnacipran in preventing PSD, a significant complication that can significantly impact stroke recovery and overall well-being. The authors emphasize the need for further research to confirm these findings and explore the optimal dosage and treatment duration for milnacipran in preventing PSD. However, these initial results offer hope for patients who have experienced stroke and are at risk for developing PSD.

Stroke Recovery: A Journey Back to Wellness

The study highlights the importance of addressing the emotional and mental health needs of stroke survivors. PSD can significantly hinder recovery and impact quality of life. As Dr. Camel, I believe that promoting mental well-being is crucial for a successful journey back to wellness after a stroke. This research suggests that medications like milnacipran may play a role in safeguarding mental health and promoting a positive outlook for stroke survivors.

Dr. Camel's Conclusion

This randomized controlled trial provides evidence for the potential of milnacipran in preventing poststroke depression. The study found a significantly lower incidence of depression in the milnacipran group compared to placebo. While further research is needed to confirm these findings and establish optimal treatment protocols, this research offers hope for stroke survivors at risk for developing poststroke depression.

Date :
  1. Date Completed 2012-05-29
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

21811172

DOI: Digital Object Identifier

10.1097/YIC.0b013e32834a5c64

Related Literature

Article Analysis
・Side Effects of milnacipran
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.